In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, ...

Explore LENN nanoparticles, a groundbreaking technology for delivering mRNA therapies to bladder cancer cells with enhanced ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine—which designs nanotechnology-based ...

In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

Developing in vivo CAR T-cell therapies requires reliable approaches for transient, controlled CAR expression and targeted mRNA delivery to immune cells. This webinar will examine the transformative ...

Researchers at the Icahn School of Medicine at Mount Sinai say they have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...